JAMA Oncol.

Bröckelmann PJ, Goergen H, Keller U, Meissner J, Ordemann R, Halbsguth TV, Sasse S, Sökler M, Kerkhoff A, Mathas S, Hüttmann A, Bormann M, Zimmermann A, Mettler J, Fuchs M, von Tresckow B, Baues C, Rosenwald A, Klapper W, Kobe C, Borchmann P, Engert A

doi: 10.1001/jamaoncol.2020.0750.

Br J Haematol

Eichenauer DA, Müller H, Elger L, Goergen H, Fuchs M, Kreissl S, Böll B, Diehl V, von Tresckow B, Borchmann P, Engert A

doi: 10.1111/bjh.17327

Picardi et al. 2020. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 4-year update of the ECHELON-1 study. Poster presentation presented at: EHA25 Virtual; 10−21 June 2020.

Lancet Oncol.

Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB, Collins G, Savage KJ, Trneny M, Kato K, Farsaci B, Parker SM, Rodig S, Roemer MG, Ligon AH, Engert A

doi: 10.1016/

N Engl J Med.

Minard-Colin V, Aupérin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, Delgado RF, Alexander S, Uyttebroeck A, Bollard CM, Zsiros J, Csoka M, Kazanowska B, Chiang AK, Miles RR, Wotherspoon A, Adamson PC, Vassal G, Patte C, Gross TG, European Intergroup for Childhood Non-Hodgkin Lymphoma the Children’s Oncology Group

doi: 10.1056/NEJMoa1915315.

Hutchings et al. Brentuximab vedotin plus chemotherapy in high risk advanced-stage classical Hodgkin lymphoma (CHL) patients: Results of pre-specified sub-group analyses from the ECHELON-1 study. EHA Annual Congress. Abstract S112. Obtained from the EHA website http://www.ehaweb.org

Br J Haematol.

Ahmed S, Ghosh N, Ahn KW, Khanal M, Litovich C, Mussetti A, Chhabra S, Cairo M, Mei M, William B, Nathan S, Bejanyan N, Olsson RF, Dahi PB, van der Poel M, Steinberg A, Kanakry J, Cerny J, Farooq U, Seo S, Kharfan-Dabaja MA, Sureda A, Fenske TS, Hamadani M

doi: 10.1111/bjh.16664.

doi: 10.1111/bjh.15676.